K. Akiyama, S. Ikezawa, Yumi Hasegawa, Y. Sugisita, Ryota Kaneko, Naoko Okamoto, Masaya Koganesawa, Sachio Fujita, Ryosuke Matsuno, D. Toyama, Hirokazu Ikeda, Shohei Yamamoto
{"title":"Neurocognitive Evaluation of Japanese Childhood Cancer Survivors","authors":"K. Akiyama, S. Ikezawa, Yumi Hasegawa, Y. Sugisita, Ryota Kaneko, Naoko Okamoto, Masaya Koganesawa, Sachio Fujita, Ryosuke Matsuno, D. Toyama, Hirokazu Ikeda, Shohei Yamamoto","doi":"10.15369/sujms.32.25","DOIUrl":null,"url":null,"abstract":": Long-term cognitive effects following acute lymphoblastic leukemia treatment have been reported for Caucasians; however, these data remain unclear for other ethnicities and the treatment of other cancers. Here, we assessed cognitive function in Japanese childhood cancer survivors. This study enrolled 53 Japanese survivors of childhood cancer ( mean age, 9.5 years; 36 boys and 17 girls ) . evaluated performance-based cognitive function using the Wechsler Intelligence Scale for Children - Fourth Edition ( WISC - Ⅳ ) . , working memory with the standardized mean and standard deviation SD; 100 and 15, respectively ) classified patients into three groups depending on the cumulative methotrexate ( MTX ) dose ( none, 1 – 19 g / m 2 , and > 20 g / m 2 ) . Full-scale among the four WISC – Ⅳ index than 20 g / m 2 , respectively; P =0.05 ) . Japanese childhood cancer survivors, including those in the non-MTX group, demonstrated significant PS impairment. High-dose MTX treatment might be associated with neurocognitive deficiencies, particularly in WM. Although current treatments are associated with high cure rates, future research and interventions are required to improve cognitive function in these patients.","PeriodicalId":23019,"journal":{"name":"The Showa University Journal of Medical Sciences","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Showa University Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15369/sujms.32.25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
: Long-term cognitive effects following acute lymphoblastic leukemia treatment have been reported for Caucasians; however, these data remain unclear for other ethnicities and the treatment of other cancers. Here, we assessed cognitive function in Japanese childhood cancer survivors. This study enrolled 53 Japanese survivors of childhood cancer ( mean age, 9.5 years; 36 boys and 17 girls ) . evaluated performance-based cognitive function using the Wechsler Intelligence Scale for Children - Fourth Edition ( WISC - Ⅳ ) . , working memory with the standardized mean and standard deviation SD; 100 and 15, respectively ) classified patients into three groups depending on the cumulative methotrexate ( MTX ) dose ( none, 1 – 19 g / m 2 , and > 20 g / m 2 ) . Full-scale among the four WISC – Ⅳ index than 20 g / m 2 , respectively; P =0.05 ) . Japanese childhood cancer survivors, including those in the non-MTX group, demonstrated significant PS impairment. High-dose MTX treatment might be associated with neurocognitive deficiencies, particularly in WM. Although current treatments are associated with high cure rates, future research and interventions are required to improve cognitive function in these patients.